Dapagrav M
Dapagliflozin + Metformin
Type 2 diabetes requiring combined SGLT2 inhibition and biguanide therapy in a single daily dose.
Each extended-release tablet contains Dapagliflozin Propanediol and Metformin Hydrochloride IP.
Immediate-release film layer over a sustained-release core — two release kinetics in one unit.
This information is intended for healthcare professionals and trade partners. The brand name applies to Graviti's own branded generics range in India; in other markets the same formulation is supplied as a generic under our filings or a partner label. Prescribing information, registration status and pack availability vary by market. Medicines should be used only under qualified medical supervision.
Dapagrav M — made to the same standard as every Graviti batch.